Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't think that Nokia ever expected there to be a triggering event. Now faced with a 1/2 billion dollar payment going forward they are using their 800lb.gorilla weight to cajole and intimidate IDCC into rate consessions. Prepay discounts and legal fees pall next to any consessions that could be gained by their tactics. Also,accruals can always be reversed if the contigent liability does not materialize.
<Otherwise, I find NOK's tactics to be odd>
Nothing is odd. Nokia is trying to weasel out of what it owes; seems to be a standard business practice in the industry.
PARS filed an S 3A today with the SEC registering the previously announced 50,000 share shelf offering.
How about a piece on 60 Minutes
Jimmy Hoffa ?
Earnings not affected. Only Balance Sheet with receipt of cash pre-payment.
To enhance the year end financials, its desirable to show the new licensing monies as received this year.
Additional comments by Merritt from the CC:
Now why should you have confidence in us? Well, many of you previously asked whether I was confident we could get the Sharp agreement renewed. I told you I was, and we got that done. You also asked if we had momentum. I said we did and subsequently signed new deals with (inaudible) and Nakayo, both of which are now contributing to recurring royalties. Our effective execution in the past should give you confidence in our ability to deliver in the future.
Yes. Especially when dealing with a foreign entity.
I think its been mentioned on this board that IDCC does not recognize a new licensee until the check is in their hands. That would imply a new licensee this year. Not familiar with SEC requirements.
Based on what's at stake vis a vis his and the company's credibility, I don't think Merritt would have even hinted at new licensees, if he were not sure of at least one this year.
Chartex: From CC (Last Sentence)
--------------------------------------------------------------------------------
Bill Merritt, InterDigital - Exec. VP, General Patent Counsel [5]
--------------------------------------------------------------------------------
Thank you and good morning to everyone. As I have done in the past, let me bring people up-to-date on the Nokia arbitration and the discussions with Samsung. Also, I will give you some additional information as to ongoing license agreement discussions and how we view the licensing landscape over the next twelve months.
As regards Nokia, the arbitration is moving forward as expected, but we are awaiting the confirmation of the third arbitrator and expect that shortly. With regard to Nokia's document access motion in Texas, the court has scheduled oral argument on that matter for November 24. At this point my expectation as to the timeframe of the Nokia arbitration remains consistent with our past disclosures, namely that the process should probably take about a year to complete. As the arbitrators become engaged in the issue, we will begin to get a better prospective on how the case will be tried and how long we would expect the case to last absent any settlement. At the Samsung, we previously reported that Samsung had initiated the contractual dispute resolution process, though neither party had just filed an arbitration request.
While Samsung has indicated its belief that arbitration appears necessary to resolve the matter, the parties continue to meet regularly. Absent the change in this position, we expect that Samsung will file an arbitration -- will file demand for arbitration in the near future. Needless to say, as Howard said, we remain very confident about both the Samsung and Nokia matters.
While Nokia and Samsung have kept us busy, we have been very occupied in other areas as well. Let me talk to you about our other activities so far this year and how I see things unfolding in the licensing program over the near and mid-term. My staff and I spent most of the last few months on the road visiting a wide range of companies. Many of those discussions have progressed beyond the basic discussions about the patents to substantive economic negotiations. Based on the progress we have seen to date and our experience with the licensing process, we remain optimistic that we will conclude additional agreements this year.
Blame it on the maid and make her buy you a new one.
JKJ
Did you notice the man and tall blonde lady from IDCC?
Posted by: Ghors
In reply to: None Date:11/25/2003 7:55:22 PM
Post #of 50192
MORE INFO:
Judge Lynn also said that NOK would in no event get any proprietary information or trade secret documents. She commented that this included pricing information of ERICY.
Lastly, IDCC and ERICy had one lawyer each. NOK had about six in attendance. To our left were three people. One man in a suit who was writing on a lawyers yellow pad. There was also a man and a tall blonde lady. After the hearing CHartex introduced himself to the man and the lady and asked them if they were from IDCC. The man said yes, but said he would answer no questions. Chartex heard them talking about trying to make a KOP flight at 6:30 and heard the man say, "I guess I better call Bill."
MY TAKE ONLY: I got the impression that Judge Lynn was not prepared to give NOK anything unless the arbitrators asked for documents they thought were relevant. Hence, I believe that if she doesn't get a request from the arbitrator's, she will not entertain any more motions on this point.
IMO
Ghors
That's "the rest of the story."
1500 shares at the ask of $20.31 went at 8:55.
I tend to agree with you. But,if Nokia's mindset is to practically accuse IDCC executives of insider trading in a document filed with the court, then IMO anything is possible. Maybe Jorma gets involved in every level of decision making, especially when he is close at hand.
Too late for Bambi. Clipped by an eighteen wheeler. LOL
OT: Speaking of Turkeys
Thanksgiving Poem
> >
> > When I was a young turkey new to the coop,
> > My big brother Mike took me out on the stoop.
> > There he sat me down and he spoke real slow,
> > And he told me there was something that I had to know.
> >
> > His look and his tone I will always remember,
> > When he told me of the horrors of Black November.
> > "Come about August, now listen to me,
> > Each day you'll get six meals instead of just three.
> >
> > "And soon you'll be thick where once you were thin,
> > And you'll grow a big rubbery thing under your chin.
> > "And then one morning when you're warm in your bed,
> > In will burst the farmer's wife, and hack off your head!
> >
> > "Then she'll pluck out all your feathers 'til you're bald 'n pink,
> > And scoop out all your insides and leave ya lyin' in the sink.
> > "And then comes the worst part," he said not bluffing,
> > "She'll spread your cheeks and pack your rear with stuffing!"
> >
> > Well, the rest of his words were too grim to repeat.
> > I sat on the stoop like a winged piece of meat,
> > And decided on the spot that to avoid being cooked,
> > I'd have to lay low and remain overlooked.
> >
> > I began a new diet of nuts and granola,
> > High-roughage salads, juice and diet cola.
> > And as they ate pastries, chocolates and crepes,
> > I stayed in my coop doing Jane Fonda tapes.
> >
> > I maintained my weight of two pounds and a half,
> > And tried not to notice when the bigger birds laughed.
> > But 'twas I who was laughing, under my breath,
> > As they chomped and they chewed, ever closer to death.
> >
> > And sure enough when Black November rolled around,
> > I was the last turkey left in the entire compound.
> > So now I'm a pet in the farmer's wife's lap;
> > I haven't a worry, so I eat and I nap.
> >
> > She held me today, while sewing and humming,
> > And smiled at me and said, "Christmas is coming..."
> > =====
Can anyone verify this:
Posted by: Walper
In reply to: chartex who wrote msg# 49688 Date:11/24/2003 9:35:28 AM
Post #of 49696
I primarily just lurk, but before anyone makes the trip to court. The hearing has been continued to November 25, at 4:30 pm per the PACER entry made Thursday. I haven't the foggiest idea why, and would not read anything into that, just moved the day...perhaps something more interesting came up.
CRIS Upgrade:
Nov 24, 2003 (financialwire.net via COMTEX) -- (FinancialWire) (Investrend Research Syndicate) ValuEngine, Inc. (www.ValuEngine.com) has upgraded five companies, including Brandywine Realty Trust (NYSE: BDN), Trizec Properties Inc. (NYSE: TRZ), ARM Holdings PLC (NASDAQ: ARMHY) and Curis, Inc. (NASDAQ: CRIS) to a "5" rating, the research firm's highest.
Off .60 to 11.83.
Maine:
from real money:
Geron a Renter, Not an Owner of Cancer Vaccine
By Adam Feuerstein
Senior Writer
11/14/2003 12:50 PM EST
Click here for more stories by Adam Feuerstein
Geron (GERN:Nasdaq - commentary - research) has been talking up its telomerase cancer vaccine targeting prostate cancer -- the young biotech firm's only drug in human clinical trials. But there's a tricky problem investors might not realize: Geron doesn't actually own the experimental vaccine.
The rights to the telomerase cancer vaccine (it doesn't yet have a more succinct name) are actually controlled jointly by Geron and a privately held biotech firm, Merix BioSciences. Under this agreement, Geron is sponsoring early studies of the vaccine, including a phase I clinical trial scheduled for completion by year-end. But Merix -- and not Geron -- has first rights to take over development of the telomerase cancer vaccine and advance it beyond phase II studies.
This means that if the experimental vaccine pans out, there's a possibility that it becomes Merix's drug to market and sell, leaving Geron with only a small slice of the proceeds. If Geron wanted to develop its own vaccine, it would essentially have to start over from scratch.
Geron shares closed Thursday at $12.43, an almost ninefold increase over its year low of $1.41 in March. Much of this investor attention, of course, is tuned to the company's work with human stem cells. It's the kind of research that gets speculative biotech investors excited, especially in a year in which riskier, small-cap biotechs have outgunned their larger, profitable counterparts.
But Geron's stem cell research is still in the early stages of development, with no products even close to human clinical trials. This is one reason why Geron management has begun talking increasingly about its more advanced cancer vaccine work, including the telomerase cancer vaccine. If Geron is going to mature into a drugmaker with actual products to sell, this is where it will happen first.
Unless, of course, Geron has to hand over its most advanced pipeline drug to Durham, N.C.-based Merix BioSciences.
Geron doesn't hide this risk from investors, but it doesn't exactly make great efforts to publicize it either. Last spring, the company announced positive preliminary results from the phase I study of the telomerase cancer vaccine, but the Merix connection was not mentioned in the company's release. In October, Geron CEO Tom Okarma made a presentation to investors at a conference sponsored by UBS, but while speaking optimistically about the vaccine, he made no mention of Merix or its rights to the drug.
Rodman & Renshaw biotech analyst Ren Benjamin, the only sell-side analyst covering Geron, according to Thomson First Call, says he wasn't aware of the Merix agreement.
Instead, Geron discloses the development risks to its telomerase cancer vaccine inside filings with the Securities and Exchange Commission, including its most recent stock registration statement:
New Job Listing in KOP: Vice President-Product Management.
If this were 1999 he might have raised us to $50.00. These guys now really do have to be conservative. No more Henry Blodgets out there.
Is that Gates on the bottom left.
You think 80,000 is low?
Don't forget the 10Q is due before 11/17. Maybe more surprises.
UBS upgrades LEXR-Just heard on Bloomberg radio.
GERN look good at these levels? TIA
A lot more riding on Monday 11/24 @ 4:30PM
Their headquarters are in my neck of the woods. Maybe I'll go over and look around someday. Impressive management.
RE: ALT
Source: Alteon
ALT-711 Improves Cardiac Function in the Aging Diabetic Heart
Monday November 10, 9:10 am ET
- Preclinical Canine Study Presented at the American Heart Association Scientific Sessions 2003 -
RAMSEY, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Alteon's lead A.G.E. Crosslink Breaker ALT-711 has been found by an independent research team to improve overall cardiac function in aged diabetic dogs by restoring left ventricular ejection fraction (LVEF), reducing aortic stiffness and reducing left ventricular (LV) mass. These changes were observed to be associated with a reversal of the overexpression of cardiac collagen seen with aging and diabetes.
ADVERTISEMENT
The study, "A Glycation End-Product Cross Link Breaker Reduces Collagen and Improves Cardiac Function in the Aging Diabetic Heart," was conducted by researchers at UMDNJ-New Jersey Medical School and presented today at the American Heart Association Scientific Sessions 2003 today in Orlando, FL. The authors propose that A.G.E. Crosslink Breakers, a class of compounds pioneered by Alteon, could provide therapeutic potential in the treatment of aged patients with diabetes. ALT-711 is under Phase 2 investigation in humans by Alteon for its potential in systolic hypertension and heart failure.
In this investigation, researchers first observed how aging and diabetes affected the structure and function of the hearts of 12 dogs, 9-12 years old. Five months of induced diabetes resulted in a 25% reduction in LVEF, a 28% decrease in stroke volume and an approximate 1.7-fold increase in aortic stiffness. Another major finding was that diabetes increased both type I and type III collagen, which accounts for roughly 96% of total collagen in the heart, by approximately 2-3 fold, contributing to an increase in LV mass. The decline of heart function and change in structure was attributed in part to the formation and crosslinking of Advanced Glycation End-products (A.G.E.s), a pathological process of aging that occurs at an accelerated rate in diabetes and has damaging effects on proteins such as collagen and elastin.
Treatment with the A.G.E. Crosslink Breaker ALT-711 over one month resulted in a reversal of these conditions, normalizing LVEH (p<0.05) and stroke volume (p<0.05). Similarly, the upregulation of collagen type I and collagen type III was reversed, contributing to a reduction in LV weight (p<0.05). In addition, myocardial LV collagen solubility increased significantly after treatment with ALT-711 (p<0.05, from 34 + or - 4.9% to 51 + or - 6.8%), which supports the breaking of A.G.E. crosslinks as the mechanism of action of ALT-711.
"This preclinical data is consistent with, and strongly supportive of, the cardiovascular activity we have seen in our human clinical trials of ALT-711 to date," said Robert C. deGroof, Ph.D., Senior Vice President Scientific Affairs. "The growing body of scientific evidence demonstrating the ability of ALT-711 to reverse certain cardiovascular complications of aging and diabetes strengthens our commitment to develop ALT-711 for the treatment of heart failure."
The study was supported by grants from the American Diabetes Association and the National Institutes of Health. An article detailing the study results is also available through PubMed, prior to its impending publication in the American Journal of Physiology (epub ahead of print at http://ajpheart.physiology.org). A previous study by the UMDNJ research group demonstrated the ability of ALT-711 to reverse cardiac stiffness in aged non-diabetic dogs, restoring the cardiovascular system to a state found in younger animals. Administration of ALT-711 daily for one month resulted in a 40% reduction in age-related ventricular stiffness (Proceedings of the National Academy of Sciences, March 14, 2000). These findings are consistent with results by other researchers in preclinical studies of ALT-711 in rats and primates.
ALT-711 is the only A.G.E. Crosslink Breaker in advanced human testing. Based on ALT-711's demonstrated efficacy and biological activity in several Phase 2 trials, as well as a strong and consistent safety profile, Alteon is proceeding with development of ALT-711 in two major cardiovascular indications, systolic hypertension and heart failure. Additional Phase 2 trials in these indications are expected to be initiated in the first half of 2004.
About Alteon
Alteon is developing several new classes of drugs that reverse or slow down diseases of aging and complications of diabetes. These compounds have an impact on a fundamental pathological process caused by protein-glucose complexes called Advanced Glycation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss of flexibility and function in body tissues, organs and vessels and have been shown to be a causative factor in many age-related diseases and diabetic complications. Alteon has created a library of novel classes of compounds targeting the A.G.E. Pathway. These include A.G.E. Crosslink Breakers, A.G.E. Formation Inhibitors and Glucose Lowering Agents. Alteon's lead compound ALT-711, the only A.G.E. Crosslink Breaker in advanced human testing, has demonstrated safety and efficacy in several Phase 2 trials and is actively being developed for systolic hypertension and heart failure. For more information on Alteon, visit the company's website at www.alteon.com.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, those relating to technology and product development (including the possibility that early clinical trial results may not be predictive of results that will be obtained in large-scale testing or that any clinical trials will not demonstrate sufficient safety and efficacy to obtain requisite approvals or will not result in marketable products), regulatory approval processes, intellectual property rights and litigation, competitive products, ability to obtain financing, and other risks identified in Alteon's filings with the Securities and Exchange Commission. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Alteon undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
--------------------------------------------------------------------------------
Source: Alteon
Email this story - Set a News Alert
CRIS News:
Source: Curis, Inc.
Curis' Hedgehog Improves Heart Function and Blood Flow in a Model of Heart Attack
Monday November 10, 8:48 am ET
Preclinical Study Nominated as Finalist for Young Investigator Award at Annual Meeting of the American Heart Association
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2003-- Curis, Inc. (NASDAQ: CRIS - News) today announced that a paper will be presented on Tuesday, November 11, 2003, demonstrating that injection of a gene encoding the Hedgehog protein results in improved cardiac function and increased blood flow to the heart in a model of myocardial ischemia. Myocardial ischemia, the interruption of blood flow and oxygen to heart muscle, is the leading cause of heart attacks. The presentation will occur at the annual Scientific Sessions of the American Heart Association being held in Orlando, Florida from November 9-12, 2003.
ADVERTISEMENT
Dr. Kengo Kusano, the first author of the paper entitled "Sonic Hedgehog Gene Therapy in Myocardial Ischemia: Transient Reconstitution of Embryonic Signaling Preserves Cardiac Function," will compete as a finalist for the Melvin L. Marcus Young Investigator Award in Cardiovascular Science that is awarded annually at the conference. The research for the study was performed in the laboratory of Dr. Douglas Losordo in the Division of Cardiovascular Research at the St. Elizabeth's Medical Center of Boston, Massachusetts. The authors conclude that administration of Hedgehog after a heart attack may have a significant advantage in promoting recovery in patients with acute myocardial ischemia by stimulating new blood vessel growth and reducing fibrosis.
Curis is developing drug candidates that activate the Hedgehog signaling pathway for the treatment of cardiovascular disease and other disorders. The National Institutes of Health estimates that approximately one million patients visit the hospital each year with some type of mycardial ischemia as their principal diagnosis.
Dr. Lee Rubin, Curis' Chief Scientific Officer, said, "Previous studies have demonstrated that Hedgehog protein can stimulate formation of new blood vessels and promote the recovery of skeletal muscle that has an insufficient blood supply. This new report now extends those observations to heart muscle and expands our understanding of the ways in which Hedgehog can be administered in order to promote the development of new blood vessels and thus increase muscle recovery."
Daniel Passeri, Curis' President and Chief Executive Officer, stated, "We believe that cardiovascular disease represents a significant new therapeutic direction for Curis. We are grateful for the opportunity to interact with Dr. Losordo and his colleagues as we begin to investigate this potential indication for Curis' drug development technologies."
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, and alopecia (hair loss). For more information, please visit the Curis web site at www.curis.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release.
--------------------------------------------------------------------------------
Contact:
For Curis, Inc.:
Chief Financial Officer
Christopher U. Missling, Ph.D., 617-503-6587
or
Vice President, Corporate Communications
Marc F. Charette, Ph.D., 617-503-6629
--------------------------------------------------------------------------------
Source: Curis, Inc.
Email this story - Set a News Alert
Sounds like you're flush with problems.
Jim....Did you see this post?
http://www.investorshub.com/boards/read_msg.asp?message_id=1678841
No. Sold in AH yesterday for $1.25. Kicking myself. May get back in if the opportunity presents itself.
Try for +.02 on this trade. LOL
Thank you for your input.